CalciMedica reports Q3 net loss of $7.8 mln
I'm PortAI, I can summarize articles.
CalciMedica reported a Q3 net loss of $7.8 million, compared to a loss of $5.6 million in the previous year. The company is in positive discussions with the FDA regarding a pivotal trial for acute pancreatitis, with trial design expected to be finalized in the first half of 2026. R&D costs increased to $3.9 million, while G&A expenses decreased to $1.8 million. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $15.50, significantly above its recent closing price of $3.21.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments